Therapeutic Targeting in Head and Neck Cancer MEDSTAT_JS MEDSTAT_CSS

Therapeutic Targeting in Head and Neck Cancer

The highly complex set of diseases that comprise head and neck cancer requires a multidisciplinary treatment approach guided by specialists in surgical, radiation, and medical oncology. In this video roundtable series, Dr Robert Haddad is joined by Dr Robert Ferris and Dr Nabil Saba for discussions of three clinical topics in the treatment of head and neck cancer: recent advances in combining chemotherapy, surgery, and radiation for the treatment of HPV-positive head and neck cancer; optimal multidisciplinary approaches to locally advanced HPV-negative disease; and the role of immune checkpoint inhibitors in the treatment of recurrent metastatic disease.

Video 1: Treating HPV-Related Head and Neck Cancer

Despite its status as a relatively new cancer, HPV-driven oropharyngeal cancer (OPC) has risen dramatically in incidence in North America in the past two decades, especially among nonsmoking, middle-aged White men. In this video, the panel discusses standards of care and trials investigating strategies for de-escalating therapy in patients with HPV+OPC.

Up Next

Video 1: Treating HPV-Related Head and Neck Cancer
Video 2: Treating Locally Advanced HPV-Negative Head and Neck Cancer
Video 3: Treating Recurrent Metastatic Head and Neck Cancer

MEDSTAT_LATEST_NEWS_WIDGET

About the Panel

Dr. Haddad Photo

Robert Haddad, MD

  • Chief; McGraw Chair, Department of Head and Neck Oncology
  • Dana-Farber Cancer Institute
  • Professor, Department of Medicine
  • Harvard Medical School
  • Boston, Massachusetts
Dr. Ferris Photo

Robert Ferris, MD, PhD

  • Hillman Professor of Oncology
  • Associate Vice Chancellor, Department of Immunology and Radiation Oncology
  • Director, UPMC Hillman Cancer Center
  • Pittsburgh, Pennsylvania
Dr. Saba Photo

Nabil F. Saba, MD

  • The Lynne and Howard Halpern Chair in Head and Neck Cancer Research
  • Emory University School of Medicine
  • Atlanta, Georgia
Disclosures

Robert Haddad, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Bristol Myers Squibb; Merck; Genentech; Pfizer; Loxo Oncology; Bayer; GSK; AstraZeneca; Merck Serono

Robert Ferris, MD, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Achilles Therapeutics; Aduro Biotech, Inc.; Bicara Therapeutics, Inc.; Bristol Myers Squibb; EMD Serono; Everest Clinical Research Corporation; F. Hoffman-La Roche Ltd.; Genocea Biosciences, Inc.; Instil Bio, Inc.; Kowa Research Institute, Inc.; Lifescience Dynamics Limited; MacroGenics, Inc.; Merck; Mirati Therapeutics, Inc.; Nanobiotix; Novasenta; Numab Therapeutics AG; Oncocyte Corporation; Pfizer; PPD Development; Rakuten Medical, Inc.; Sanofi; Seagen, Inc.; Zymeworks, Inc.
Received research grant from: AstraZeneca; Bristol Myers Squibb; Novasenta; Tesaro
Have a 5% or greater equity interest in: Novasenta

Nabil F. Saba, MD, has disclosed the following financial relationships:
Received research grant from: Bristol Myers Squibb
Received income in an amount equal to or greater than $250 from: GSK; Merck